Endothelium-restricted overexpression of human endothelin-1 causes vascular remodeling and endothelial dysfunction

Circulation

Volumn 110, Issue 15, 2004, Pages 2233-2240

  Amiri, Farhad ^a   Virdis, Agostino ^a   Fritsch Neves, Mario ^a   Iglarz, Marc ^a   Seidah, Nabil G ^a   Touyz, Rhian M ^a   Reudelhuber, Timothy L ^a   Schiffrin, Ernesto L ^a  

^a CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

Author keywords

Cardiovascular diseases; Endothelin; Endothelium; Free radicals; Remodeling

Indexed keywords

ANGIOPOIETIN RECEPTOR; ENDOTHELIN 1; ENDOTHELIN 3; ENDOTHELIN B RECEPTOR; MESSENGER RNA; OXIDIZING AGENT; PREPROENDOTHELIN 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; VASOCONSTRICTOR AGENT;

ADOLESCENT; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVATION; EXPERIMENTAL MODEL; GENE EXPRESSION; GENE OVEREXPRESSION; GENE TARGETING; HISTOGENESIS; HYPERTENSION; HYPERTROPHY; MALE; MOUSE; MOUSE STRAIN; NEWBORN; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RESISTANCE BLOOD VESSEL; TRANSGENIC MOUSE; VASCULAR ENDOTHELIUM; VASCULAR REMODELING;

ANIMALS; ANTIOXIDANTS; ENDOTHELIN-1; ENDOTHELIN-3; ENDOTHELIUM, VASCULAR; HUMANS; HYPERTROPHY; MALE; MESENTERIC ARTERIES; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, TRANSGENIC; NADPH OXIDASE; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B; RECEPTOR, TIE-2; RECOMBINANT FUSION PROTEINS; RNA, MESSENGER; VASCULAR RESISTANCE; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS; VASODILATOR AGENTS;

EID: 5644247979     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000144462.08345.B9     Document Type: Article

References (43)

1. Schiffrin EL. Endothelin: potential role in hypertension and vascular hypertrophy. Hypertension. 1995;25:1135-1143.
2. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411-415.
3. Wagner OF, Christ G, Wojta J, et al. Polar secretion of endothelin-1 by cultured endothelial cells. J Biol Chem. 1992;267:16066-16068.
4. Miyauchi T, Masaki T. Pathophysiology of endothelin in the cardiovascular system. Annu Rev Physiol. 1999;61:391-415.
5. Schiffrin EL. Role of endothelin-1 in hypertension and vascular disease. Am J Hypertens. 2001;14:83S-89S.
6. Kurihara Y, Kurihara H, Suzuki H, et al. Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1. Nature. 1994:368:703-710.
7. Berthiaume N, Yanagisawa M, Yanagisawa H, et al. Pharmacology of endothelins in vascular circuits of normal or heterozygous endothelin-A or endothelin-B knockout transgenic mice. J Cardiaovasc Pharmacol. 1998;31(suppl 1):S561-S564.
8. Hosoda K, Hammer RE, Richardson JA, et al. Targeted and natural (piebald-lethal) mutations of endothelin-B receptor gene produce megacolon associated with spotted coat color in mice. Cell. 1994;79:1267-1276.
9. Puffenberger EG, Hosoda K, Washington SS, et al. A missense mutation of the endothelin-B receptor gene in multigenic Hirschsprung's disease. Cell. 1994;79:1257-1266.
10. Yanagisawa H, Yanagisawa M, Kapur RP, et al. Dual genetic pathways of endothelin-mediated intercellular signaling revealed by targeted disruption of endothelin converting enzyme-1 gene. Development. 1998;125:825-836.
11. Yanagisawa H, Hammer RE, Richardson JA, et al. Disruption of ECE-1 and ECE-2 reveals a role for endothelin-converting enzyme-2 in murine cardiac development. J Clin Invest. 2000;105:1373-1382.
12. Hocher B, Thone-Reineke C, Rohmeiss P, et al. Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension. J Clin Invest. 1997;99:1380-1389.
13. Shindo T, Kurihara H, Maemura K, et al. Renal damage and salt-dependent hypertension in aged transgenic mice overexpressing endothelin-1. J Mol Med. 2002;80:105-116.
14. Li JS, Larivière R, Schiffrin EL. Effect of nonselective endothelin antagonist on vascular remodeling in DOCA-salt hypertensive rats: evidence for a role of endothelin in vascular hypertrophy. Hypertension. 1994;24:183-188.
15. Schiffrin EL, Larivière R, Li JS, et al. Deoxycorticosterone acetate plus salt induces overexpression of vascular endothelin-1 and severe vascular hypertrophy in spontaneously hypertensive rats. Hypertension. 1995;25:769-773.
16. Duerrschmidt N, Wippich N, Goettsch W, et al. Endothelin-1 induces NAD(P)H oxidase in human endothelial cells. Biochem Blophys Res Commun. 2000;269:713-717.
17. Li L, Fink GD, Watts SW, et al. Endothelin-1 increases vascular Superoxide via endothelin A-NADPH oxidase pathway in low-renin hypertension. Circulation. 2003;107:1053-1058.
18. Intengan HD, Schiffrin EL. Structure and mechanical properties of resistance arteries in hypertension. Hypertension. 2000;36:312-318.
19. Mulvany MJ, Baumbach GL, Aalkjaer C, et al. Vascular remodeling. Hypertension, 1996;28:505-506.
20. Intengan HD, Schiffrin EL. Vascular remodeling in hypertension: roles of apoptosis and fibrosis. Hypertension. 2001;38:581-587.
21. d'Uscio LV, Barton M, Shaw S, et al. Structure and function of small arteries in salt-induced hypertension: effects of chronic endothelin-subtype-A- receptor blockade. Hypertension. 1997;30:905-911.
22. Li L, Watts SW, Banes AK, et al. NADPH oxidase-derived Superoxide augments endothelin-1-induced venoconstriction in mineralocorticoid hypertension. Hypertension. 2003;42:316-321.
23. Cai H, Griendling KK, Harrison DG. The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases. Trends Pharmacol Sci. 2003;24:471-478.
24. Schlaeger TM, Bartunkova S, Lawitts JA, et al. Uniform vascular-endothelial-cell-specific gene expression in both embryonic and adult transgenic mice. Proc Natl Acad Sci U S A. 1997;94:3058-3063.
25. Itoh Y, Yanagisawa M, Ohkubo S, et al. Cloning and sequence analysis of cDNA encoding the precursor of a human endothelium-derived vasoconstrictor peptide, endothelin: identity of human and porcine endothelin. FEBS Lett. 1988:231:440-444.
26. Lochard N, Silversides DW, van Kats JP, et al. Brain-specific restoration of angiotensin II corrects renal defects seen in angiotensinogen-deficient mice. J Biol Chem. 2003;278:2184-2189.
27. Miller AL, Plane F, Jeremy JY, et al. Delayed recovery of receptor-mediated functional responses to Ach in mouse isolated carotid arteries following endothelial denudation in vivo. J Vasc Res. 2003;40:449-459.
28. Iglarz M, Touyz RM, Amiri F, et al. Effect of peroxisome proliferator-activated receptor-α and -y activators on vascular remodeling in endothelin-dependent hypertension. Arterioscler Thromb Vasc Biol. 2003;23:45-51.
29. Day R, Larivière R, Schiffrin EL. In situ hybridization shows increased endothelin-1 mRNA levels in endothelial cells of blood vessels of deoxycorticosterone acetate-salt hypertensive rats. Am J Hypertens. 1995;8:294-300.
30. Schiffrin EL, Larivière R, Li JS, et al. Enhanced expression of the endothelin-1 gene in blood vessels of DOCA-salt hypertensive rats: correlation with vascular structure. J Vasc Res. 1996;33:235-248.
31. Carlson SH, Wyss JM. Long-term telemetric recording of arterial pressure and heart rate in mice fed basal and high NaCl diets. Hypertension. 2000;35:1e-5e.
32. Yin FC, Spurgeon HA, Rakusan K, et al. Use of tibial length to quantify cardiac hypertrophy: application in the aging rat. Am J Physiol. 1982;243:H941-H947.
33. Miller AL, Plane F, Jeremy JY, et al. Delayed recovery of receptor-mediated functional responses to acetylcholine in mouse isolated carotid arteries following endothelial denudation in vivo. J Vasc Res. 2003;40:449-59.
34. Heagerty AM, Aalkjaer C, Bund SJ, et al. Small artery structure in hypertension: dual process of remodeling and growth. Hypertension. 1993;21:391-397.
35. Virdis A. Iglarz M, Neves MF, et al. Effect of hyperhomocystinemia and hypertension on endothelial function in methylenetetrahydrofolate reductase-deficient mice. Arterioscler Thromb Vasc Biol. 2003;23:1352-1357.
36. Diep QN, El Mabrouk M, Conn JS et al. Structure, endothelial function, cell growth and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-γ. Circulation. 2002;105:2296-2302.
37. Ammarguellat F, Larouche I, Schiffrin EL. Myocardial fibrosis in DOCA-salt hypertensive rats: effect of endothelin ETA receptor antagonism. Circulation. 2001;103:319-324.
38. Mortensen LH, Fink GD. Salt-dependency of endothelin-induced, chronic hypertension in conscious rats. Hypertension. 1992;19:549-554.
39. Chatziantoniou C, Boffa JJ, Ardaillou R. et al. Nitric oxide inhibition induces early activation of type 1 collagen gene in renal resistance vessels and glomeruli in transgenic mice: role of endothelin. J Clin Invest. 1998;101:2780-2789.
40. Wedgwood S, Dettman RW, Black SM. ET-1 stimulates pulmonary arterial smooth muscle cell proliferation via induction of reactive oxygen species. Am J Physiol. 2001;281:L1058-L1067.
41. Park JB, Touyz RM, Chen X, et al. Chronic treatment with a Superoxide dismutase mimetic prevents vascular remodeling and progression of hypertension in salt-loaded stroke-prone spontaneously hypertensive rats. Am J Hypertens. 2002;15:78-84.
42. Sedeek MH, Llinas MT, Drummond H, et al. Role of reactive oxygen species in endothelin-induced hypertension. Hypertension. 2003;42:806-810.
43. Tomasian D, Keaney JF, Vita JA. Antioxidants and the bioactivity of endothelium-derived nitric oxide. Cardiovasc Res. 2000;47:426-435.